MX349950B - Profarmacos de treprostinil enlazados a un portador. - Google Patents
Profarmacos de treprostinil enlazados a un portador.Info
- Publication number
- MX349950B MX349950B MX2014001497A MX2014001497A MX349950B MX 349950 B MX349950 B MX 349950B MX 2014001497 A MX2014001497 A MX 2014001497A MX 2014001497 A MX2014001497 A MX 2014001497A MX 349950 B MX349950 B MX 349950B
- Authority
- MX
- Mexico
- Prior art keywords
- carrier
- prodrugs
- linked treprostinil
- treprostinil prodrugs
- compounds
- Prior art date
Links
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 title abstract 3
- 229960005032 treprostinil Drugs 0.000 title abstract 3
- 239000000651 prodrug Substances 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177409 | 2011-08-12 | ||
| EP11195615 | 2011-12-23 | ||
| EP12165508 | 2012-04-25 | ||
| PCT/EP2012/065745 WO2013024052A1 (en) | 2011-08-12 | 2012-08-10 | Carrier-linked treprostinil prodrugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014001497A MX2014001497A (es) | 2014-04-25 |
| MX349950B true MX349950B (es) | 2017-08-22 |
Family
ID=46690494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014001497A MX349950B (es) | 2011-08-12 | 2012-08-10 | Profarmacos de treprostinil enlazados a un portador. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9561287B2 (enExample) |
| EP (1) | EP2741781A1 (enExample) |
| JP (1) | JP6092867B2 (enExample) |
| KR (1) | KR101997939B1 (enExample) |
| CN (1) | CN103857413A (enExample) |
| AU (1) | AU2012296954B2 (enExample) |
| BR (1) | BR112014003225A2 (enExample) |
| CA (1) | CA2843883C (enExample) |
| HK (1) | HK1198359A1 (enExample) |
| IL (1) | IL230712A (enExample) |
| IN (1) | IN2014CN00989A (enExample) |
| MX (1) | MX349950B (enExample) |
| WO (1) | WO2013024052A1 (enExample) |
| ZA (1) | ZA201400977B (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1198359A1 (en) * | 2011-08-12 | 2015-04-10 | Ascendis Pharma A/S | Carrier-linked treprostinil prodrugs |
| AU2013254756B2 (en) * | 2012-04-25 | 2017-03-30 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
| US9913912B2 (en) | 2012-12-07 | 2018-03-13 | Ascendis Pharma A/S | Carrier-linked prostanoid prodrugs |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| EP4137127A1 (en) | 2013-01-11 | 2023-02-22 | Corsair Pharma, Inc. | Prodrugs of treprostinil |
| CA2908244C (en) * | 2013-03-25 | 2021-04-20 | United Therapeutics Corporation | Process of making prostacyclin compounds with linker thiol and pegylated forms |
| CN105407883A (zh) * | 2013-04-30 | 2016-03-16 | 联合治疗学有限公司 | 控释药物制剂 |
| KR102296259B1 (ko) | 2013-10-25 | 2021-08-30 | 인스메드 인코포레이티드 | 프로스타사이클린 화합물, 조성물 및 이의 사용 방법 |
| TWI685348B (zh) * | 2014-05-08 | 2020-02-21 | 美國禮來大藥廠 | 速效胰島素組合物 |
| WO2015192030A1 (en) * | 2014-06-13 | 2015-12-17 | United Therapeutics Corporation | Treprostinil formulations |
| WO2016010538A1 (en) * | 2014-07-16 | 2016-01-21 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| AU2015349969B2 (en) | 2014-11-18 | 2020-02-06 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
| TWI540121B (zh) | 2014-12-01 | 2016-07-01 | 臺灣永光化學工業股份有限公司 | 曲前列環素二乙醇胺之合成方法及新穎中間體 |
| US10632129B2 (en) * | 2014-12-03 | 2020-04-28 | Steadymed Ltd. | Preservative-free treprostinil formulations and methods and devices for use with same |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US11389510B2 (en) | 2016-01-08 | 2022-07-19 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
| MX2018008050A (es) | 2016-01-08 | 2018-08-23 | Ascendis Pharma Growth Disorders As | Agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada con estabilidad endopeptidasa neutral (nep) incrementada. |
| WO2017118693A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
| SI3400019T1 (sl) | 2016-01-08 | 2023-01-31 | Ascendis Pharma Growth Disorders Division A/S | Predzdravila CNP s povezavo nosilca na obročni ostanek |
| CA3008017C (en) | 2016-01-08 | 2024-01-02 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| IL297375B2 (en) | 2016-01-08 | 2024-02-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with low NPR–C binding |
| CN109069659B (zh) | 2016-03-01 | 2022-04-19 | 阿森迪斯药物骨疾病股份有限公司 | Pth前药 |
| US11896671B2 (en) | 2016-07-13 | 2024-02-13 | Ascendis Pharma A/S | Conjugation method for carrier-linked prodrugs |
| SI3512495T1 (sl) * | 2016-09-15 | 2023-01-31 | Camurus Ab | Formulacije prostaciklinskih analogov |
| NZ792622A (en) | 2016-09-29 | 2025-08-29 | Ascendis Pharma Bone Diseases As | Pth compounds with low peak-to-trough ratios |
| IL304086A (en) | 2016-09-29 | 2023-08-01 | Ascendis Pharma Bone Diseases As | Dosing regimen for a controlled-release PTH compound |
| DK3518982T3 (da) | 2016-09-29 | 2025-02-03 | Ascendis Pharma Bone Diseases As | Pth-forbindelser med kontrolleret frigivelse |
| HUE062117T2 (hu) | 2016-09-29 | 2023-09-28 | Ascendis Pharma Growth Disorders As | Kombinációs terápia szabályozott felszabadulású CNP agonistákkal |
| EP3498283A1 (en) | 2017-12-14 | 2019-06-19 | Ipsol AG | Glycosidic derivatives of treprostinil |
| AU2019270464B2 (en) | 2018-05-18 | 2024-09-26 | Ascendis Pharma Bone Diseases A/S | Starting dose of PTH conjugates |
| IL281690B2 (en) | 2018-09-26 | 2025-01-01 | Ascendis Pharma As | New hydrogel bracelets |
| IL281695B2 (en) | 2018-09-26 | 2025-08-01 | Ascendis Pharma As | Degradable hyaluronic acid hydrogels |
| CA3114056A1 (en) | 2018-09-26 | 2020-04-02 | Ascendis Pharma A/S | Treatment of infections |
| CA3125479A1 (en) | 2019-01-04 | 2020-07-09 | Ascendis Pharma Oncology Division A/S | Sustained local drug levels for innate immune agonists |
| CA3125541A1 (en) | 2019-01-04 | 2020-07-09 | Ascendis Pharma Oncology Division A/S | Minimization of systemic inflammation |
| CA3125488A1 (en) | 2019-01-04 | 2020-07-09 | Ascendis Pharma Oncology Division A/S | Induction of sustained local inflammation |
| MX2021007706A (es) | 2019-01-04 | 2021-08-05 | Ascendis Pharma Oncology Div A/S | Conjugados de agonistas de receptor de reconocimiento de patron. |
| EP3923906A1 (en) | 2019-02-11 | 2021-12-22 | Ascendis Pharma Growth Disorders A/S | Dry pharmaceutical formulations of cnp conjugates |
| MY209748A (en) | 2019-02-11 | 2025-07-31 | Ascendis Pharma Bone Diseases As | Liquid pharmaceutical formulations of pth conjugates |
| CN114072136B (zh) | 2019-04-29 | 2024-11-29 | 英斯梅德股份有限公司 | 曲前列素前药的干粉组合物及其使用方法 |
| WO2020254611A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 conjugates |
| WO2020254612A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Controlled-release tyrosine kinase inhibitor compounds with localized pd properties |
| WO2020254617A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 compounds with localized pk properties |
| WO2020254607A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 compounds with localized pd properties |
| TW202114660A (zh) | 2019-06-21 | 2021-04-16 | 丹麥商阿仙帝斯製藥公司 | 酪胺酸激酶抑制劑結合物 |
| WO2020254613A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Controlled-release tyrosine kinase inhibitor compounds with localized pk properties |
| JP2020011957A (ja) * | 2019-07-22 | 2020-01-23 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| CA3161101A1 (en) | 2020-01-13 | 2021-07-22 | Kennett Sprogoe | Hypoparathyroidism treatment |
| WO2021224169A1 (en) | 2020-05-04 | 2021-11-11 | Ascendis Pharma A/S | Hydrogel irradiation |
| CN116113415A (zh) | 2020-06-09 | 2023-05-12 | 联合治疗公司 | 曲前列尼尔的富马酰基二酮哌啶前药 |
| MX2023003540A (es) | 2020-09-28 | 2023-04-21 | Ascendis Pharma Bone Diseases As | Mejora del bienestar fisico y mental de los pacientes con hipoparatiroidismo. |
| JP7138685B2 (ja) * | 2020-10-26 | 2022-09-16 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| TW202246206A (zh) * | 2021-03-16 | 2022-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種曲前列環素衍生物及其用途 |
| IL311539A (en) | 2021-09-22 | 2024-05-01 | Ascendis Pharma Bone Diseases As | Long-acting pth compound treatments |
| AU2022409306A1 (en) | 2021-12-13 | 2024-06-06 | Ascendis Pharma Oncology Division A/S | Cancer treatments with tlr7/8 agonists |
| WO2023110758A1 (en) | 2021-12-13 | 2023-06-22 | Ascendis Pharma Growth Disorders A/S | Effective doses of cnp conjugates |
| CN116444377A (zh) * | 2022-01-07 | 2023-07-18 | 广州楷石医药有限公司 | 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途 |
| IL316466A (en) | 2022-05-23 | 2024-12-01 | Ascendis Pharma Growth Disorders As | Liquid pharmaceutical formulations of cnp compounds |
| AU2023374533A1 (en) | 2022-11-02 | 2025-04-10 | Ascendis Pharma Bone Diseases A/S | Pth treatment regimen comprising two pth compounds |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| CN121219011A (zh) | 2023-03-20 | 2025-12-26 | 阿森迪斯药物生长障碍股份有限公司 | 治疗患有软骨发育不全患者胸腰椎畸形的方法 |
| WO2025051711A1 (en) | 2023-09-04 | 2025-03-13 | Ascendis Pharma Bone Diseases A/S | Pth treatment of chronic kidney disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4306075A (en) | 1980-03-28 | 1981-12-15 | The Upjohn Company | Composition and process |
| CA1241324A (en) | 1984-03-08 | 1988-08-30 | Paul A. Aristoff | Interphenylene carbacyclin derivatives |
| CA2359652A1 (en) | 1999-03-31 | 2000-10-05 | United Therapeutics Corporation | Novel prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of peripheral vascular disease and pulmonaryhypertension |
| CA2843439A1 (en) * | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd | Reversible pegylated drugs |
| ES2331187T3 (es) * | 2003-12-16 | 2009-12-23 | United Therapeutics Corporation | Utilizacion de treprostinil para mejorar las funciones renales. |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| EP1625856A1 (en) | 2004-08-13 | 2006-02-15 | Complex Biosystems GmbH | Hydrogel polymeric conjugates of a prodrug |
| EP2120961A1 (en) * | 2007-02-09 | 2009-11-25 | United Therapeutics Corporation | Treprostinil treatment for interstitial lung disease and asthma |
| EP2173890B1 (en) * | 2007-06-21 | 2011-03-16 | Technische Universität München | Biological active proteins having increased in vivo and/or vitro stability |
| CA2721947C (en) | 2008-04-29 | 2016-03-08 | Ascendis Pharma As | Pegylated recombinant human growth hormone compounds |
| US8575102B2 (en) | 2008-08-01 | 2013-11-05 | Nektar Therapeutics | Conjugates having a releasable linkage |
| US8637466B2 (en) * | 2008-08-11 | 2014-01-28 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
| US20110166063A1 (en) * | 2008-09-19 | 2011-07-07 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
| EP2370068A4 (en) * | 2008-12-10 | 2015-09-23 | Paka Pulmonary Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR DELIVERING MEDICAMENTS TO THE LUNG |
| WO2010144508A1 (en) | 2009-06-08 | 2010-12-16 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
| SG177761A1 (en) * | 2009-07-31 | 2012-03-29 | Ascendis Pharma As | Biodegradable polyethylene glycol based water-insoluble hydrogels |
| EP2485767A1 (en) * | 2009-10-06 | 2012-08-15 | Ascendis Pharma A/S | Carrier linked paliperidone prodrugs |
| HK1198359A1 (en) * | 2011-08-12 | 2015-04-10 | Ascendis Pharma A/S | Carrier-linked treprostinil prodrugs |
-
2012
- 2012-08-10 HK HK14111870.6A patent/HK1198359A1/xx unknown
- 2012-08-10 AU AU2012296954A patent/AU2012296954B2/en not_active Ceased
- 2012-08-10 MX MX2014001497A patent/MX349950B/es active IP Right Grant
- 2012-08-10 US US14/238,437 patent/US9561287B2/en active Active
- 2012-08-10 WO PCT/EP2012/065745 patent/WO2013024052A1/en not_active Ceased
- 2012-08-10 KR KR1020147006343A patent/KR101997939B1/ko not_active Expired - Fee Related
- 2012-08-10 CN CN201280049725.9A patent/CN103857413A/zh active Pending
- 2012-08-10 JP JP2014524413A patent/JP6092867B2/ja not_active Expired - Fee Related
- 2012-08-10 CA CA2843883A patent/CA2843883C/en not_active Expired - Fee Related
- 2012-08-10 EP EP12748194.3A patent/EP2741781A1/en not_active Withdrawn
- 2012-08-10 IN IN989CHN2014 patent/IN2014CN00989A/en unknown
- 2012-08-10 BR BR112014003225A patent/BR112014003225A2/pt not_active Application Discontinuation
-
2014
- 2014-01-29 IL IL230712A patent/IL230712A/en active IP Right Grant
- 2014-02-10 ZA ZA2014/00977A patent/ZA201400977B/en unknown
-
2017
- 2017-01-27 US US15/418,180 patent/US10729778B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL230712A0 (en) | 2014-03-31 |
| EP2741781A1 (en) | 2014-06-18 |
| HK1198359A1 (en) | 2015-04-10 |
| JP6092867B2 (ja) | 2017-03-08 |
| KR20140070545A (ko) | 2014-06-10 |
| BR112014003225A2 (pt) | 2017-03-01 |
| JP2014527050A (ja) | 2014-10-09 |
| CA2843883C (en) | 2020-04-28 |
| KR101997939B1 (ko) | 2019-07-08 |
| AU2012296954B2 (en) | 2016-09-15 |
| CN103857413A (zh) | 2014-06-11 |
| IN2014CN00989A (enExample) | 2015-04-10 |
| IL230712A (en) | 2017-08-31 |
| US10729778B2 (en) | 2020-08-04 |
| AU2012296954A1 (en) | 2014-02-20 |
| WO2013024052A1 (en) | 2013-02-21 |
| US9561287B2 (en) | 2017-02-07 |
| MX2014001497A (es) | 2014-04-25 |
| ZA201400977B (en) | 2017-11-29 |
| CA2843883A1 (en) | 2013-02-21 |
| US20140296150A1 (en) | 2014-10-02 |
| US20190105400A1 (en) | 2019-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX349950B (es) | Profarmacos de treprostinil enlazados a un portador. | |
| EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
| PH12017501429A1 (en) | Derivatives of betulin | |
| WO2012122340A8 (en) | Soluble guanylate cyclase activators | |
| IN2014CN02616A (enExample) | ||
| JO3091B1 (ar) | مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها | |
| MY187718A (en) | Pharmaceutical formulations | |
| IN2014KN00948A (enExample) | ||
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| CA2830549C (en) | Methods and compositions for preparing noribogaine from voacangine | |
| IN2012DN02139A (enExample) | ||
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| EA201170198A1 (ru) | Фармацевтические композиции, содержащие лиганды рецептора дофамина | |
| MX2014004196A (es) | Citramida de rasagilina. | |
| TN2014000112A1 (en) | Ep1 receptor ligands | |
| MA37866A1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| EA201270818A1 (ru) | 6-(1-МЕТИЛ-1H-ПИРАЗОЛ-4-ИЛ)-3-(2-МЕТИЛ-2H-ИНДАЗОЛ-5-ИЛТИО)-[1,2,4]ТРИАЗОЛ-[43-b]ПИРИДАЗИН В КАЧЕСТВЕ ИНГИБИТОРА c-МЕТ | |
| EA201300990A1 (ru) | Парентеральное введение тапентадола | |
| WO2010150211A3 (en) | Use of derivatives of indoles for the treatment of cancer | |
| EA033171B1 (ru) | Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол | |
| MY168212A (en) | A new therapeutical composition containing apomorphine as active ingredient | |
| PH12013502204A1 (en) | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists | |
| MX2011011776A (es) | Nuevos profarmacos de triptolite. | |
| WO2013040227A3 (en) | Therapeutic compounds | |
| WO2011132051A3 (en) | Tricycle compounds as phosphodiesterase-10 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |